Changrong Ziben, formally known as Xiamen Changrong Investment Management, is an investment firm that focuses on equity investments across various sectors, including innovative medicines, medical devices, artificial intelligence, semiconductors, new energy, and education. The firm is staffed by experienced professionals who possess deep industry knowledge and expertise in capital operation. Changrong Ziben excels in resource integration and fund management, which allows it to identify and support promising entrepreneurial teams and enterprises with significant growth potential. In addition to financial support, the firm offers a range of services, including capital operation, financial advisory, and industrial operation, aimed at enhancing the overall value of its portfolio companies.
NAKI Therapeutics is a research-focused biopharmaceutical company developing Chimeric Antigen Receptor (CAR)-Natural Killer (NK) immunotherapy used to kill cancer cells effectively and safely compared to existing treatments. The company was founded in 2020 and is headquartered in Summit, New Jersey.
Amberstone Biosciences discovers novel immunotherapies through innovative technologies and creative partnerships. Amberstone's focus is difficult targets requiring a unique mode-of-action and/or particular functional property, which are otherwise challenging for traditional approaches. These conventional limitations are overcome via a two-pronged approach. First, we have demonstrated success with our microfluidics-powered AmberFlow drug-discovery platform. Second, our team of experts has keen insights in immuno-oncology and ample experience with single-cell assay biology.
Eubulus
Series A in 2021
Eubulus is an early-stage company focusing on building a platform technology for therapeutic enhancement. The company specializes in Proteolysis- targeting chimeras (PROTACSs).
Anji Pharmaceuticals is focused on tackling high-value targets validated by human genetics. We are exhaustive in our discovery and clinical efforts while nimble in our strategy and execution. We have assembled a world-class team of scientist entrepreneurs who are committed to accelerate innovative medicines in China and worldwide.
VivaVision Biotech is a clinical-stage R&D biopharmaceutical company that is developing novel medicines to treat topical diseases. VivaVision Biotech is dedicated to bringing new therapeutics to millions of patients suffering from chronic ocular or dermal inflammatory diseases.
Focus-X Therapeutics is a preclinical-stage biotechnology company that specializes in the development of radiopharmaceuticals for cancer treatment. The company aims to address unmet needs in cancer diagnosis and therapy by employing a theragnostic approach, particularly targeting solid tumors with low five-year survival rates. Focus-X Therapeutics is advancing its proprietary radioligand therapy, which utilizes alpha and beta emitters to precisely disrupt cancer cell DNA. By optimizing peptide ligand vectors, the company seeks to create innovative theranostic agents that offer medical practitioners new mechanisms for treating cancer effectively.
Elgia Therapeutics is a biotechnology company focused on developing innovative treatments for chronic inflammatory and fibrotic diseases. The company employs novel approaches in drug discovery, utilizing high-throughput chemical screening and structure-based design to identify and develop small molecule inhibitors targeting specific protein pathways. By understanding the role of metabolic stress in driving inflammation and fibrosis, Elgia Therapeutics aims to create effective therapies for patients suffering from debilitating chronic conditions. Its commitment to advancing healthcare through the development of these targeted treatments positions it as a significant player in the pharmaceutical and therapeutic landscape.
Proviva Therapeutics
Seed Round in 2020
Proviva Therapeutics is a pro-drug design platform for cytokines and other fusion proteins. It is committed to solving the problem of drug metabolism and the delivery of cytogenic drugs.
Shengshi Huaneng is committed to the collection, purification, and comprehensive utilization of methane-based greenhouse gases such as urban and rural agricultural and forestry biomass fermentation biogas, coal mine gas, and industrial tail gas, as well as distributed energy and other carbon emission reduction fields, to help China's carbon neutral development strategy.
EO Company is a technology and industry innovation service platform that specializes in the large health sector. Its core offerings include health technology media, industry business conferences, and research consultations. Targeting the business end of the health industry, EO Company provides a range of online products such as industry content planning, video columns, and consulting services. The platform is designed to facilitate connections within the industry chain and offers insights backed by high market attention and an international perspective. By focusing on technological and industrial innovation, EO Company aims to support the advancement of the health sector in China.
Onlyou offers advanced solutions and services focused on finance and taxation for large and medium-sized enterprises, as well as administrative institutions. Leveraging artificial intelligence, cloud computing, and big data technology, the company aims to simplify and enhance financial and tax management. Its intelligent tax platform delivers comprehensive financial and tax support, allowing clients to access crucial services with increased efficiency and accuracy. By combining innovative technology with extensive practical experience in the financial sector, Onlyou addresses the complex needs of its clientele in the finance and taxation landscape.
Arthrosi Therapeutics is a biotechnology company dedicated to drug discovery and development, with a specific focus on therapies for gout and chronic kidney disease. The company is engaged in clinical-stage research aimed at reducing flare-ups and tophi in gout patients. By developing innovative treatments, Arthrosi Therapeutics enables healthcare professionals to achieve significant uric acid reduction and address joint damage associated with tophi, thereby improving patient outcomes in these conditions.
The pharmaceutical industry has struggled to identify small molecule inhibitors of PCSK9 function. This has been explained by the expansive but flat binding interface between PCSK9 and the LDL receptor, spanning nearly 800 square angstroms. To date, only monoclonal antibodies have been able to target this region of PCSK9. We have discovered bona fide small molecule inhibitors of PCSK9 function that are orally bioavailable across multiple preclinical species. Guided by dozens of high-resolution x-ray structures of our molecules bound to PCSK9, we have utilized structure-based design to achieve picomolar affinity.
wanmen.org is an online education platform that provides multiple courses.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.